330 related articles for article (PubMed ID: 34101496)
1. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study).
Hulshof MCCM; Geijsen ED; Rozema T; Oppedijk V; Buijsen J; Neelis KJ; Nuyttens JJME; van der Sangen MJC; Jeene PM; Reinders JG; van Berge Henegouwen MI; Thano A; van Hooft JE; van Laarhoven HWM; van der Gaast A
J Clin Oncol; 2021 Sep; 39(25):2816-2824. PubMed ID: 34101496
[TBL] [Abstract][Full Text] [Related]
2. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
Jeene PM; Versteijne E; van Berge Henegouwen MI; Bergmann JJ; Geijsen ED; Muller K; van Laarhoven HW; Hulshof MC
Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27766725
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity.
Ristau J; Thiel M; Katayama S; Schlampp I; Lang K; Häfner MF; Herfarth K; Debus J; Koerber SA
Radiat Oncol; 2021 Feb; 16(1):23. PubMed ID: 33522923
[TBL] [Abstract][Full Text] [Related]
4. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197
[TBL] [Abstract][Full Text] [Related]
5. High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial.
You J; Zhu S; Li J; Li J; Shen J; Zhao Y; Li X; Jia L; Li Q; Yang J; Wu Y; Shen W; Wu H; Wu X; Wang X; Ren Y; He J; Lin P; Zhu G; Shi A
Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1129-1137. PubMed ID: 36402359
[TBL] [Abstract][Full Text] [Related]
6. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer.
Dreyfuss AD; Barsky AR; Wileyto EP; Eads JR; Kucharczuk JC; Williams NN; Karasic TB; Metz JM; Ben-Josef E; Plastaras JP; Wojcieszynski AP
Cancer Med; 2021 Feb; 10(4):1275-1288. PubMed ID: 33474812
[TBL] [Abstract][Full Text] [Related]
8. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
Smit JK; Muijs CT; Burgerhof JG; Paardekooper G; Timmer PR; Muller K; Woutersen D; Mul VE; Beukema JC; Hospers GA; van Dijk BA; Langendijk JA; Plukker JT
Ann Surg Oncol; 2013 Jun; 20(6):1985-92. PubMed ID: 23274534
[TBL] [Abstract][Full Text] [Related]
9. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.
Suntharalingam M; Winter K; Ilson D; Dicker AP; Kachnic L; Konski A; Chakravarthy AB; Anker CJ; Thakrar H; Horiba N; Dubey A; Greenberger JS; Raben A; Giguere J; Roof K; Videtic G; Pollock J; Safran H; Crane CH
JAMA Oncol; 2017 Nov; 3(11):1520-1528. PubMed ID: 28687830
[TBL] [Abstract][Full Text] [Related]
10. The role of definitive chemoradiation in patients with non-metastatic oesophageal cancer.
Jeene PM; van Laarhoven HWM; Hulshof MCCM
Best Pract Res Clin Gastroenterol; 2018; 36-37():53-59. PubMed ID: 30551857
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
[TBL] [Abstract][Full Text] [Related]
13. Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders.
Greally M; Chou JF; Molena D; Rusch VW; Bains MS; Park BJ; Wu AJ; Goodman KA; Kelsen DP; Janjigian YY; Ilson DH; Ku GY
J Thorac Oncol; 2019 Mar; 14(3):540-546. PubMed ID: 30391577
[TBL] [Abstract][Full Text] [Related]
14. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern.
Versteijne E; van Laarhoven HW; van Hooft JE; van Os RM; Geijsen ED; van Berge Henegouwen MI; Hulshof MC
Dis Esophagus; 2015 Jul; 28(5):453-9. PubMed ID: 24725186
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus.
Münch S; Pigorsch SU; Devečka M; Dapper H; Feith M; Friess H; Weichert W; Jesinghaus M; Braren R; Combs SE; Habermehl D
Radiat Oncol; 2019 Apr; 14(1):66. PubMed ID: 30992022
[TBL] [Abstract][Full Text] [Related]
16. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma.
Haj Mohammad N; Hulshof MC; Bergman JJ; Geijsen D; Wilmink JW; van Berge Henegouwen MI; van Laarhoven HW
BMC Cancer; 2014 Jan; 14():56. PubMed ID: 24485047
[TBL] [Abstract][Full Text] [Related]
17. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus.
Münch S; Pigorsch SU; Devečka M; Dapper H; Weichert W; Friess H; Braren R; Combs SE; Habermehl D
Radiat Oncol; 2018 Aug; 13(1):139. PubMed ID: 30068371
[TBL] [Abstract][Full Text] [Related]
18. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Chen J; Yin W; Yao H; Gu W
Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
[TBL] [Abstract][Full Text] [Related]
19. Endostatin and Oxaliplatin-Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study.
Li W; Chen P; Zhang N; Song T; Wu S
Oncologist; 2019 Apr; 24(4):461-e136. PubMed ID: 30850562
[TBL] [Abstract][Full Text] [Related]
20. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K
BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
